ATE213414T1 - Verwendung von 2,4-diaminopyrimidin-3-oxyd und/oder seine salze zur behandlungvon störungen der kollagenreifung oder -strukturierung - Google Patents

Verwendung von 2,4-diaminopyrimidin-3-oxyd und/oder seine salze zur behandlungvon störungen der kollagenreifung oder -strukturierung

Info

Publication number
ATE213414T1
ATE213414T1 AT95931260T AT95931260T ATE213414T1 AT E213414 T1 ATE213414 T1 AT E213414T1 AT 95931260 T AT95931260 T AT 95931260T AT 95931260 T AT95931260 T AT 95931260T AT E213414 T1 ATE213414 T1 AT E213414T1
Authority
AT
Austria
Prior art keywords
pct
structuring
oxyde
diaminopyrimidine
salts
Prior art date
Application number
AT95931260T
Other languages
English (en)
Inventor
Yann Mahe
Lionel Breton
Jean-Baptiste Galey
Bruno Bernard
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of ATE213414T1 publication Critical patent/ATE213414T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95931260T 1994-09-19 1995-09-19 Verwendung von 2,4-diaminopyrimidin-3-oxyd und/oder seine salze zur behandlungvon störungen der kollagenreifung oder -strukturierung ATE213414T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9411133A FR2724561B1 (fr) 1994-09-19 1994-09-19 Utilisation du 2,4-diamino pyrimidine 3-oxyde ou de l'un de ses sels dans le traitement des desordres de la maturation et de la structuration du collagene
PCT/FR1995/001197 WO1996009048A1 (fr) 1994-09-19 1995-09-19 Utilisation du 2,4-diamino pyrimidine 3-oxyde ou de l'un de ses sels dans le traitement des desordres de la maturation et de la structuration du collagene

Publications (1)

Publication Number Publication Date
ATE213414T1 true ATE213414T1 (de) 2002-03-15

Family

ID=9467049

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95931260T ATE213414T1 (de) 1994-09-19 1995-09-19 Verwendung von 2,4-diaminopyrimidin-3-oxyd und/oder seine salze zur behandlungvon störungen der kollagenreifung oder -strukturierung

Country Status (22)

Country Link
US (1) US5846552A (de)
EP (1) EP0783307B1 (de)
JP (1) JP2945482B2 (de)
KR (1) KR100250939B1 (de)
CN (1) CN1070702C (de)
AT (1) ATE213414T1 (de)
AU (1) AU691336B2 (de)
BR (1) BR9508841A (de)
CA (1) CA2199995C (de)
CZ (1) CZ284476B6 (de)
DE (1) DE69525539T2 (de)
DK (1) DK0783307T3 (de)
ES (1) ES2171550T3 (de)
FI (1) FI971127A (de)
FR (1) FR2724561B1 (de)
HU (1) HU223143B1 (de)
MX (1) MX9701996A (de)
NO (1) NO311784B1 (de)
PL (1) PL186385B1 (de)
PT (1) PT783307E (de)
RU (1) RU2153874C2 (de)
WO (1) WO1996009048A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69831186T2 (de) * 1997-04-30 2006-06-08 Jsr Corp. Orientierungsschicht für Flüssigkristall und Verfahren zu ihrer Herstellung
US7763587B2 (en) 2002-06-13 2010-07-27 L'oreal S.A. Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
FR2871688B1 (fr) 2004-06-16 2008-05-16 Oreal Procede pour favoriser la penetration d'un actif et composition permettant sa mise en oeuvre
US7300649B2 (en) 2005-02-11 2007-11-27 Genepharm, Inc. Cosmetic and cosmeceutical compositions for restoration of skin barrier function
FR2902324B1 (fr) * 2006-06-20 2009-04-03 Oreal Utilisation d'acide ellagique pour le traitement de la canitie
EP1897533A1 (de) * 2006-09-08 2008-03-12 Revotar Biopharmaceuticals AG Verwendung von 1,6-Bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl]hexan zur Herstellung von kosmetischen Zusammensetzungen
EP1946756A1 (de) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Verwendung von Entacapon für kosmetische, dermatologische und pharmazeutische Zusammensetzungen
BRPI0916690B1 (pt) 2008-07-29 2022-04-12 L'oreal Uso de uma quantidade eficaz de pelo menos um microorganismo probiótico, composição coméstica e/ou dermatólogica, método coméstico para tratar e/ou prevenir distúrbios estéticos do couro cabeludo em um indivíduo, processo cosmético para prevenir e/ou tratar uma condição de caspa do couro cabeludo, conjunto cosmético, e, uso cosmético de pelo menos uma quantidade eficaz de pelo menos um primeiro e um segundo agente cosmético ativo
FR2951938B1 (fr) 2009-10-30 2012-01-06 Oreal Utilisation d'un extrait de punica granatum pour lutter contre la canitie
CN104398418A (zh) * 2014-11-06 2015-03-11 陈爱华 一种防脱发护发素
FR3130153A1 (fr) 2021-12-15 2023-06-16 L'oreal Utilisation d’au moins un dérivé de pyrimidine 3-oxyde pour renforcer la fonction barrière de la peau

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049902A3 (de) * 1980-10-15 1982-09-01 Teijin Limited Thiazol(3,2-a)pyrimidinderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
FR2644460A1 (fr) * 1989-03-16 1990-09-21 Oreal Esters retinoiques de d-desosamine, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
LU87766A1 (fr) * 1990-07-20 1992-03-11 Oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre
CA2085954A1 (en) * 1991-12-24 1993-06-25 Klaus Weidmann Substituted pyridine n-oxides, processes for their preparation, and their use

Also Published As

Publication number Publication date
PT783307E (pt) 2002-07-31
EP0783307B1 (de) 2002-02-20
PL186385B1 (pl) 2004-01-30
WO1996009048A1 (fr) 1996-03-28
JPH10506886A (ja) 1998-07-07
CA2199995C (fr) 2002-01-15
JP2945482B2 (ja) 1999-09-06
CN1159755A (zh) 1997-09-17
US5846552A (en) 1998-12-08
AU691336B2 (en) 1998-05-14
FR2724561A1 (fr) 1996-03-22
FI971127A0 (fi) 1997-03-18
NO971182L (no) 1997-05-14
FR2724561B1 (fr) 1996-12-13
CN1070702C (zh) 2001-09-12
KR100250939B1 (ko) 2000-05-01
NO311784B1 (no) 2002-01-28
FI971127A (fi) 1997-03-18
DE69525539T2 (de) 2002-09-26
HUT76796A (en) 1997-11-28
CA2199995A1 (fr) 1996-03-28
EP0783307A1 (de) 1997-07-16
DE69525539D1 (de) 2002-03-28
HU223143B1 (hu) 2004-03-29
CZ284476B6 (cs) 1998-12-16
ES2171550T3 (es) 2002-09-16
NO971182D0 (no) 1997-03-14
BR9508841A (pt) 1999-05-04
MX9701996A (es) 1997-06-28
DK0783307T3 (da) 2002-06-03
AU3476595A (en) 1996-04-09
KR970705998A (ko) 1997-11-03
PL319279A1 (en) 1997-08-04
CZ84297A3 (en) 1997-08-13
RU2153874C2 (ru) 2000-08-10

Similar Documents

Publication Publication Date Title
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69533176D1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
ATE204174T1 (de) Verwendung von teilchen eines bioverträglichen und bioresorbierbaren kalziumsalzes als wirkstoff in der herstellung eines arzneimittels zur lokalen behandlung von entkalkungskrankheiten
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
DE69634748D1 (de) Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums
ATE213414T1 (de) Verwendung von 2,4-diaminopyrimidin-3-oxyd und/oder seine salze zur behandlungvon störungen der kollagenreifung oder -strukturierung
DE69600084D1 (de) Verwendung von hydroxylierte Carbonsäure zur Behandlung von Nägeln
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE68904462D1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
ATE217514T1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
ATE220915T1 (de) Einen basischen fibroblastwachstumsfaktor enthaltende mittel zur behandlung von knochenkrankheiten
ATE239458T1 (de) Verwendung von selegilin zur behandlung von epileptischen erkrankungen
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ATE230608T1 (de) Verwendung von bradykinin-antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimer'schen krankheit
ATE265444T1 (de) D-ring modifizierte gibberellinverbindungen und ihre herstellung und verwendung
ATE203671T1 (de) Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen
ATE399551T1 (de) Hilfsmittel und methoden zur transdermalen applikation von felodipin
ATE221528T1 (de) Neue 1,4-dihydropyridinderivate und deren therapeutische anwendung
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee